A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 7, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

August 31, 2011

Conditions
Cancer of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionCancer of the Stomach
Interventions
DRUG

Vandetanib

Vandetanib 100mg orally escalating to doses of 200 mg daily 7 days a week until completion of radiation therapy

DRUG

5 Fluorouracil (FU)

5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy

DRUG

Carboplatin

Carboplatin AUC=5 days 1 and 29 during radiation therapy

DRUG

Paclitaxel

Paclitaxel 50 mg/m2 days 1, 8, 15, 22, 29 during radiation therapy

RADIATION

External Beam Radiation Therapy (RT)

External Beam Radiation Therapy(XRT)to a total dose of 4,500 centiGray (cGy) (180 cGy fractions daily) Monday through Friday for five weeks

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Fox Chase Cancer Center

OTHER